Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Gross Margin (2022 - 2025)

Arcutis Biotherapeutics has reported Gross Margin over the past 4 years, most recently at 90.69% for Q4 2025.

  • Quarterly results put Gross Margin at 90.69% for Q4 2025, up 64.0% from a year ago — trailing twelve months through Dec 2025 was 90.08% (down 8.0% YoY), and the annual figure for FY2025 was 90.14%, up 162.0%.
  • Gross Margin for Q4 2025 was 90.69% at Arcutis Biotherapeutics, down from 91.25% in the prior quarter.
  • Over the last five years, Gross Margin for ARQT hit a ceiling of 96.06% in Q3 2023 and a floor of 62.9% in Q3 2022.
  • Median Gross Margin over the past 4 years was 88.24% (2024), compared with a mean of 85.84%.
  • Biggest five-year swings in Gross Margin: surged 3316bps in 2023 and later plummeted -836bps in 2024.
  • Arcutis Biotherapeutics' Gross Margin stood at 83.62% in 2022, then dropped by 0bps to 83.39% in 2023, then increased by 8bps to 90.04% in 2024, then grew by 1bps to 90.69% in 2025.
  • The last three reported values for Gross Margin were 90.69% (Q4 2025), 91.25% (Q3 2025), and 90.81% (Q2 2025) per Business Quant data.